Lung-MAP: Screening for Previously-Treated Non-Small Cell Lung Cancer
This study, called Lung-MAP, is for people with non-small cell lung cancer that has been treated before. It's a screening study that looks at samples from your tumor to see if you qualify for other related studies. These related studies compare new targeted cancer treatments, designed to block cancer growth, or combinations of treatments, to standard care. The goal is to find new treatments that work well. This study will look for specific markers in your tumor, like PD-1 and PD-L1, to help decide which related study might be best for you. The study aims to screen up to 10,000 people.
- Study design
- This is an interventional screening platform study that aims to enroll up to 10,000 participants.
- What's involved
- You would submit tissue samples, and potentially whole blood for ctDNA (circulating tumor DNA) testing if a fresh biopsy is needed. The screening process could take up to 3 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Screening success is measured for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
1229 sites across 51 statesStudy leadership
- Hossein Borghaei · STUDY_CHAIR · SWOG Cancer Research Network
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Screening Success (Tissue Submission)Up to 3 years
The tissue submission will be measured by the proportion of patients who register to this screening study for whom a tissue sample is submitted.
- Screening Success (Adequate Tissue)Up to 3 years
Adequate tissue will be measured by the proportion of patients who submitted a specimen for whom genomic results were successfully obtained, if multiple platforms are being used (e.g. both FMI and IHC), these rates will be summarized by the individual assays and combined. These rates are summarized for the entire screened population and by screening type (screened at progression versus pre-screened prior to progression). The rates are evaluated for both the initial submission success rates and the overall success rate accounting for new tissue submissions following an unsuccessful result.
- Screening Success (Prescreening-to-sub-study Assignment)Up to 3 years
Pre-screening-to-sub-study assignment will be measured among pre-screened patients and the proportion of patients assigned to a sub-study (which is triggered by the submission of the notice of progression form, see Section 14.0). Note: Patients screened at progression are notified of their sub-study assignment within 1 day of the biomarker results being reported to SWOG.
- Screening Success (Notice of Intention Not to Register Submission)Up to 3 years
Screening success will be measured by the reasons for non-participation collection on the LungMAP Notice of Intention not to Register Form. The proportions of patients with this form submitted are summarized overall and by screening type. The reasons for submission are summarized overall and by screening type.
- Screening Success (Match to Biomarker-Driven Sub-Study)Up to 3 years
Match to Biomarker-Driven Sub-Study will be measured by successful biomarker screening, the proportion assigned to a biomarker-driven substudy.
- Screening Success (Assignment Success)Up to 3 years
Assignment Success will be measured by the proportion of patients assigned to a sub-study who are registered to a sub-study, these rates are summarized overall and among biomarker-driven and non-match sub-study assignments, separately. In addition, these rates are summarized by screening type.